International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency

被引：162
作者：
Lichtman, Stuart M.
Wildiers, Hans
Launay-Vacher, Vincent
Steer, Christopher
Chatelut, Etienne
Aapro, Matti [1 ]
机构：
[1] Doyen IMO Clin Genolier, CH-1272 Genolier, Switzerland
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[4] Hop La Pitie Salpetriere, Paris, France
[5] Univ Toulouse 3, F-31062 Toulouse, France
[6] Inst Claudius Regaud, Toulouse, France
来源：
EUROPEAN JOURNAL OF CANCER | 2007年 / 43卷 / 01期
关键词：
clinical practice recommendations; elderly; cancer; renal insufficiency; creatinine clearance; serum creatinine; dosing adjustments;
D O I：
10.1016/j.ejca.2006.11.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A SIOG taskforce was formed to discuss best clinical practice for elderly cancer patients with renal insufficiency This manuscript outlines recommended dosing adjustments for cancer drugs in this population according to renal function. Dosing adjustments have been made for drugs in current use which have recommendations in renal insufficiency and the elderly, focusing on drugs which are renally eliminated or are known to be nephrotoxic. Recommendations are based on pharmacokinetic and/or pharmacodynamic data where available. The taskforce recommend that before initiating therapy, some form of geriatric assessment should be conducted that includes evaluation of comorbidities and polypharmacy, hydration status and renal function (using available formulae). Within each drug class, it is sensible to use agents which are less likely to be influenced by renal clearance. Pharmacokinetic and pharmacodynamic data of anticancer agents in the elderly are needed in order to maximise efficacy whilst avoiding unacceptable toxicity. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码：14 / 34
页数：21
相关论文
共 266 条
  • [61] CREAVEN PJ, 1976, CANCER TREAT REP, V60, P445
  • [62] Methotrexate pharmacokinetics and effects in women receiving methotrexate 50 mg and 60 mg per square meter for early abortion
    Creinin, MD
    Krohn, MA
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1997, 177 (06) : 1444 - 1449
  • [63] CROOKE ST, 1977, CANCER TREAT REP, V61, P1631
  • [64] CROOKE ST, 1977, CANCER, V39, P1430, DOI 10.1002/1097-0142(197704)39:4<1430::AID-CNCR2820390412>3.0.CO
  • [65] 2-V
  • [66] CURT GA, 1983, CANCER RES, V43, P4470
  • [67] THE ASSOCIATION BETWEEN HIGH-DOSE CYTARABINE NEUROTOXICITY AND RENAL-INSUFFICIENCY
    DAMON, LE
    MASS, R
    LINKER, CA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (10) : 1563 - 1568
  • [68] TREATMENT OF HYPERCALCEMIA WITH PAMIDRONATE IN PATIENTS WITH END-STAGE RENAL-FAILURE
    DAVENPORT, A
    GOEL, S
    MACKENZIE, JC
    [J]. SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1993, 27 (04): : 447 - 451
  • [69] Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide
    deJong, RS
    Mulder, NH
    Uges, DRA
    Kaul, S
    Winograd, B
    Sleijfer, DT
    Groen, HJM
    Willemse, PHB
    vanderGraaf, WTA
    deVries, EGE
    [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (11) : 1660 - 1666
  • [70] Hemolytic uremic syndrome as a complication of gemcitabine treatment:: report of six cases and review of the literature
    Desramé, J
    Duvic, C
    Bredin, C
    Béchade, D
    Artru, P
    Brézault, C
    Defuentes, G
    Poirier, JM
    Dourthe, LM
    Coutant, G
    Chaussade, S
    de Gramont, A
    Algayres, JP
    [J]. REVUE DE MEDECINE INTERNE, 2005, 26 (03): : 179 - 188
234567891011